Technology | August 11, 2014

FDA Clears Medtronic’s Attain Performa Quadripolar Lead and Viva Quad CRT-Ds

New system helps physicians deliver CRT efficiently to heart failure patients

Medtronic Viva Quad XT CRT-D Adaptiv CRT

The Medtronic Viva Quad XT CRT-D with AdaptivCRT technology

Medtronic Viva Quad XT CRT-D Adaptiv CRT

The Medtronic Viva Quad XT CRT-D with AdaptivCRT technology

Medtronic Viva Quad XT CRT-D Adaptiv CRT

The Medtronic Viva Quad XT CRT-D with AdaptivCRT technology

August 11, 2014 — Medtronic announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D). The quadripolar lead and devices will be broadly available to physicians in mid-September.

With 16 pacing configurations and shorter spacing between the two center electrodes, the Attain Performa model 4298 left-heart lead provides additional options for physicians to treat different patient anatomies. The new quadripolar lead reduces the incidence of phrenic nerve stimulation (PNS), a potential side effect that results in muscle twitching, hiccups or shortness of breath. The Viva Quad XT device is equipped with the proprietary AdaptivCRT feature, which preserves normal heart rhythms and automatically adjusts to patients’ needs to customize therapy. The system includes VectorExpress technology, which reduces lead programming time to two minutes by providing physicians with clinically actionable information to help them select optimal pacing configurations for each patient.

Quadripolar leads help physicians optimize CRT delivery. The Attain Performa lead addresses the clinical challenges that can compromise lead position, offering implanting physicians more options to maintain lead position and optimize CRT. The model 4298 lead has a canted shape and steroid on all four electrodes for lower pacing thresholds.

“Compared to conventional leads, the additional pacing configurations offered by this system provide implanting physicians more options to optimize CRT delivery, which results in better patient care. Likewise, the narrow-spaced bipole helps avoid phrenic nerve capture,” said George H. Crossley, M.D., FACC, FHRS, associate professor, Vanderbilt Heart and Vascular Institute, Nashville.

The AdaptivCRT algorithm is the first significant advance to improve patient response rates to CRT since the advent of the therapy more than 10 years ago. The benefits of the algorithm were demonstrated in the Adaptive CRT trial, a prospective, multicenter, randomized, double blind clinical trial. Key findings from the original trial, sub-analyses and economic models included:

  • For patients with normal AV conduction, AdaptivCRT showed an increase in CRT response rate of 12 percent at six months;
  • Patients with AdaptivCRT demonstrated a 21 percent reduction in heart failure hospitalizations as compared to historical CRT trials;
  • Patients with the AdaptivCRT technology demonstrated a 46 percent reduced risk of AF8, and a 61 percent lower risk of AF-related problems; and
  • AdaptivCRT demonstrated a reduction in 30-day hospital readmissions for heart failure of 47 percent.


“Medtronic continues to advance the care of heart failure patients, as it has since it first commercialized CRT in the United States. With the previously available AdaptivCRT algorithm, and now the new Attain Performa canted lead and Viva Quad devices, Medtronic is delivering a top-notch system for patients with heart failure,” said David Steinhaus, M.D., vice president and general manager, Heart Failure, and medical director for the Cardiac Rhythm and Heart Failure Management business at Medtronic.

For more information: www.medtronic.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init